Humacyte Announces Acceptance of Marketing Authorization Application for Symvess® in Israel

Humacyte, Inc. announced that the Israel Ministry of Health has accepted its Marketing Authorization Application for Symvess®, an acellular tissue engineered vessel, aimed at vascular trauma repair. The review period is set for 180 working days, following previous FDA approval. Humacyte intends to expand the availability of Symvess globally to address the needs of patients with severe vascular injuries.